Quick answer
What is Petrelintide?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
Petrelintide is a peptide, grouped on this site under Amylin and amylin receptor agonists, and the 6 research records kept here are 2 from studies in rats or mice, 1 from a trial in people and 3 that do not state what kind of study it is.
The literature search returned 8 records. This site keeps 6 of them, which is 75 per cent of what came back.
What it is
This site puts it in the Amylin and amylin receptor agonists group.
A long-acting human amylin analogue, per the retrieved records.[1]
Stated in the title of the cited 2025 Journal of Medicinal Chemistry paper.
What kind of records
A small number of the records kept here are trials in people.
That sentence is produced by counting, not by reading. What was counted: 1 interventional human trial record among 6 indexed records.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 2 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue. Journal of medicinal chemistry (2025). pmid:41217931